Freenome Company

By decoding cell-free biomarker patterns of once unthinkable complexity, Freenome’s medical artificial intelligence (AI) platform is poised to detect cancer at its earliest stages and help clinicians optimize the next generation of precision therapies.
Freenome is a health technology company developing accurate, accessible and non-invasive disease screening products for proactively treating cancer and other diseases at their most manageable stages. Freenome aims to reinvent disease management through systematized early detection and intervention. Since launching in 2014, the company has raised more than $70 million from leading technology and healthcare investors.
Technology: Non-clinical Applications
Industry: AI for Longevity
Headquarters: United States
Founded Date: 2012
Employees Number: 51-200
Funding Status: Early Stage Venture
Investors Number: 36
Total Funding: $507.6M
Estimated Revenue: $10M to $50M
Last Funding Type: Series C

Visit Website
Register and Claim Ownership